[HTML][HTML] A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A Negro, M Curto, L Lionetto, P Martelletti - The Journal of Headache and …, 2015 - Springer
Background The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
[PDF][PDF] A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A Negro, M Curto, L Lionetto, P Martelletti - World Health, 2016 - core.ac.uk
Background: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: A real-world experience.
A Negro, M Curto, L Lionetto… - The Journal of Headache …, 2015 - psycnet.apa.org
Background: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A Negro, M Curto, L Lionetto… - The Journal of …, 2016 - search.proquest.com
Background The efficacy and safety of OnabotulinumtoxinA (BOTOX) in adults with chronic
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
A Negro, M Curto, P Martelletti… - Journal of Headache & …, 2016 - search.ebscohost.com
Background: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
A Negro, M Curto, L Lionetto… - The Journal of Headache …, 2015 - europepmc.org
Background The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
[HTML][HTML] A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A Negro, M Curto, L Lionetto… - The Journal of Headache …, 2015 - ncbi.nlm.nih.gov
Background The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
[引用][C] A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A Negro, M Curto, L Lionetto, P Martelletti - The Journal of Headache …, 2015 - cir.nii.ac.jp
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse
headache: a real-world experience | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
headache: a real-world experience | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A Negro, M Curto, L Lionetto… - The journal of …, 2015 - pubmed.ncbi.nlm.nih.gov
Background The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in …
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache. a real-world experience
A Negro, M Curto, L Lionetto… - THE JOURNAL OF …, 2015 - iris.uniroma1.it
BACKGROUND: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …
chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage …